MediciNova shares surged 85% after-hours after a study showed its drug tipelukast (MN-001) and metabolite MN-002 improve cholesterol clearance, potentially preventing artery plaque. Published in the Journal of Atherosclerosis and Thrombosis, the findings strengthen the drug case in metabolic and heart diseases. Retail traders cheered the monster move.